On May 8, 2026, BioCardia, Inc. reported a positive outcome from its FDA Pre-Submission Meeting for the Helix device, which received no safety concerns and has two pathways for marketing clearance. The FDA favored simultaneous approval with their CardiAMP cell therapy system for heart failure treatment.